NCT01022853 2018-07-30Combination of BI6727 (Volasertib) and BIBF1120 in Solid TumorsBoehringer IngelheimPhase 1 Completed30 enrolled 24 charts
NCT00715403 2014-12-02A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120Boehringer IngelheimPhase 1 Completed41 enrolled 24 charts